C3a Is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation

Journal of Experimental Medicine

Volumn 181, Issue 6, 1995, Pages 2119-2127

  Daffern, Pamela J ^a   Pfeifer, Philippe H ^a   Ember, Julia A ^a   Hugli, Tony E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A;

ANTIBODY RESPONSE; ARTICLE; CELL POLARITY; CELL STIMULATION; ENZYME ACTIVATION; ENZYME PURIFICATION; ENZYME RELEASE; EOSINOPHIL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTOSIS; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CHEMOTAXIS, LEUKOCYTE; COMPARATIVE STUDY; COMPLEMENT 3A; COMPLEMENT 5A; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; GLUCURONIDASE; HUMAN; KINETICS; MOLECULAR SEQUENCE DATA; NEUTROPHIL ACTIVATION; NEUTROPHILS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0029000948     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.181.6.2119     Document Type: Article

References (63)

1. Hugli, T.E., and H.J. Muller Eberhard. 1978. Anaphylatoxins: C3a and C5a. Adv. Immunol. 26: 1-53.
2. Ward, P.A., and L.J. Newman. 1969. A neutrophil chemotactic factor from human C’5. J. Immunol. 102: 93-99.
3. Henson, P.M. 1971. The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. J. Immunol. 107: 1535-1546.
4. Goetzl, E.G., and K.F. Austen. 1974. Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J. Clin. Invest. 53: 591-599.
5. Wardlaw, A.J., R. Moqbel, O. Cromwell, and A.B. Kay. 1986. Platelet-activating factor: a potent chemotactic and chemoki-netic factor for human eosinophils. J. Clin. Invest. 78: 1701-1706.
6. Morita, E., J.-M. Schroder, and E. Christophers. 1989. Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins. Scand. J. Immunol. 29: 709-716.
7. Altman, L.C., J.S. Hill, W.H. Hairfield, and M.F. Mullarkey. 1981. Effects of corticosteroids on eosinophil chemotaxis and adherence. J. Clin. Invest. 67: 28-36.
8. Bruijnzeel, P.L.B., P.H.M. Kuijper, S. Rihs, S. Betz, R.A.J. Warringa, and L. Koenderman. 1993. Eosinophil migration in atopic dermatitis. I. Increased migratory responses to N-formyl-methionyl-leucyl-phenylalanine, neutrophil-activating factor, platelet-activating factor, and platelet factor 4. J. Invest. Dermatol. 100: 137-142.
9. Morita, E., J.-M. Schroder, and E. Christophers. 1989. Chemotactic responsiveness of eosinophils isolated from patients with inflammatory skin diseases. J. Dermatol. 16: 348-351.
10. Warringa, R.A.J., H.J.J. Mengelers, P.H.M. Kuijper, J.A.M. Raaijmakers, P.L.B. Bruijnzeel, and L. Koenderman. 1992. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals. Blood. 79:1836-1841.
11. Gerard, N.P., M.K. Hodges, J.M. Drazen, P.F. Weller, and C. Gerard. 1989. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J. Biol. Chem. 264: 1760-1766.
12. Fukuoka, Y., and T.E. Hugh. 1988. Demonstration of a specific C3a receptor on guinea pig platelets. J. Immunol. 140: 3496-3501.
13. Fukuoka, Y., T. Tachibana, and A. Yasui. 1994. Anaphylatoxin C3a induces rapid protein phosphorylation in guinea pig platelets. Immunopharmacology. 28: 95-104.
14. Mousli, M., T.E. Hugli, Y. Landry, and C. Bronner. 1992. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol 148: 2456-2461.
15. Kajita, T., and T.E. Hugli. 1991. Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg. Am. J. Pathol 183: 1-11.
16. Damerau, B., E. Grunefeld, and W. Vogt. 1980. Aggregation of leukocytes induced by the complement-derived peptides C3a and C5a and by three synthetic formyl-methionyl peptides. Int. Arch. Allergy Appl. Immunol. 63: 159-169.
17. Showell, H.J., M.M. Glovsky, and P.A. Ward. 1982. C3a-induced lysosomal enzyme secretion from human neutrophils. Lack of inhibition by t met-leu-phe antagonists and inhibition by arachidonic acid antagonists. Int. Arch. Allergy Appl. Immunol. 67: 227-232.
18. Nagata, S., M.M. Glovsky, and S.L. Kunkel. 1987. Anaphyla-toxin-induced neutrophil chemotaxis and aggregation. Limited aggregation and specific desensitization induced by human C3a and synthetic C3a octapeptides. Int. Arch. Allergy Appl. Immunol. 82: 4-9.
19. Showell, H.J., M.M. Glovsky, and P.A. Ward. 1982. Morphological changes in human polymorphonuclear leukocytes induced by C3a in the presence and absence of cytochalasin B. Int. Arch. Allergy. Appl. Immunol 69: 62-67.
20. Fernandez, H.N., P.M. Henson, A. Otani, and T.E. Hugli. 1978. Chemotactic response to human C3a and C5a anaphyla-toxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions. J. Immunol, 120:109-115.
21. Hugli, T.E. 1989. Structure and function of C3a anaphylatoxin. Curr. Top. Microbiol. Immunol 153: 181-208.
22. Gerardy-Schahn, R., D. Ambrosius, D. Saunders, M. Casaretto, C. Mittler, G. Karwarth, S. Gorgen, andD. Bitter-Suermann. 1989. Characterization of C3a receptor-proteins on guinea pig platelets and human polymorphonuclear leukocytes. Eur. J. Immunol. 19: 1095-1102.
23. Klos, A., S. Bank, C. Gietz, W. Bautsch, J. Kohl, M. Burg, and T. Kretzschmar. 1992. C3a receptor on dibutyryl-cAMP-differendated U937 cells and human neutrophils: the human C3a receptor characterized by functional responses and 125I-C3a binding. Biochemistry. 31: 11274-11282.
24. Norgauer, J., G. Dobos, E. Kownatzki, C. Dahinden, R. Burger, R. Kupper, and P. Gierschik. 1993. Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. Eur. J. Biochem. 217: 289-294.
25. Glovsky, M.M., T.E. Hugli, T. Ishizaka, L.M. Lichtenstein, and B.W. Erickson. 1979. Anaphylatoxin-induced histamine release with human leukocytes. Studies of C3a leukocyte binding and histamine release. J. Clin. Invest. 64: 804-811.
26. Van Epps, D.E., and D.E. Chenoweth. 1984. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. J. Immunol. 132: 2862-2867.
27. Hartman, C.T., Jr., and M.M. Glovsky. 1981. Complement activation requirements for histamine release from human leukocytes: influence of purified C3ai, u and C5ahu on histamine release. Int. Arch. Allergy Appl. Immunol. 66: 274-281.
28. Bischoff, S.C., A.L. de Week, and C.A. Dahinden. 1990. Interleukin 3 and granulocyte/macrophage-colony-stimulation factor render human basophils responsive to low concentrations of complement component C3a. Proc. Natl. Acad. Sci. USA. 87: 6813-6817.
29. Kretzschmar, T., A. Jeromin, C. Gietz, W. Bautsch, A. Klos, J. Kohl, G. Rechkemmer, and D. Bitter-Suermann. 1993. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur. J. Immunol. 23: 558-561.
30. Goers, J.W., M.M. Glovsky, M.W. Hunkapiller, V. Farnsworth, and J.H. Richards. 1984. Studies on C3ahu binding to human eosinophils: characterization of binding. Int. Arch. Allergy Appl. Immunol. 74: 147-151.
31. Eisner, J., M. Oppermann, W. Czech, G. Dobos, E. Schopf, J. Norgauer, and A. Kapp. 1994. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur. J. Immunol. 24: 518-522.
32. Bischoff, S.C., M. Krieger, S. Takafuji, VV. Tscharner, M. Baggliolini, and C.A. Dahinden. 1992. C3a is a potent agonist of human eosinophils. Eighth Int. Cong. Immunol. 161. (Abstr.)
33. Takafuji, S., K. Tadokoro, K. Ito, and C.A. Dahinden. 1994. Degranulation from human eosinophils stimulated with C3a and C5a. Int. Arch. Allergy Immunol. 104: 27-29.
34. Fukuoka, Y., A. Yasui, and T. Tachibana. 1991. Active recombinant C3a of human anaphylatoxin produced in Escherichia coli. Biochem. Biophys. Res. Commun. 175: 1131-1138.
35. Morgan, E.L., J.A. Ember, S.D. Sanderson, W. Scholz, R. Buchner, R.D. Ye, and T.E. Hugli. 1993. Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J. Immunol. 151: 377-388.
36. Hugli, T.E., C. Gerard, M. Kawahara, M.E. Scheetz II, R. Barton, S. Briggs, G. Koppel, and S. Russell. 1981. Isolation of three separate anaphylatoxins from complement-activated human serum. Mol. Cell Biochem. 41: 59-66.
37. Ferrante, A., and Y.H. Thong. 1978. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J. Immunol. Methods. 24: 389-393.
38. Ferrante, A., and Y.H. Thong. 1980. Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method. J. Immunol Methods. 36: 109-117.
39. Gartner, I. 1980. Separation of human eosinophils in density gradients of polyvinylpyrrolidone-coated silica gel (Fercoll). Immunology. 40: 133-136.
40. Hansel, T.T., I J.M. De Vries, T. Iff, S. Rihs, M. Wandzilak, S. Betz, K. Blaser, and C. Walker. 1991. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J. Immunol. Methods. 145: 105-110.
41. Smith, C.W., J.C. Hollers, R.A. Patrick, and C. Hassett. 1979. Motility and adhesiveness in human neutrophils: effects of chemotactic factors. J. Clin. Invest. 63: 221-229.
42. Ember, J.A., S.D. Sanderson, S.M. Taylor, M. Kawahara, and T. E. Hugli. 1992. Biologic activity of synthetic analogues of C5a anaphylatoxin. J. Immunol 148: 3165-3173.
43. Jorg, A., J.-M. Pasquier, andS.J. Klebanoff. 1982. Purification of horse eosinophil peroxidase. Biochim. Biophys. Acta. 701: 185-191.
44. Schrdeder, J.M., U. Mrowietz, E. Moritz, and E. Christophers. 1987. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin-1 activity. J. Immunol. 139: 3474-3483.
45. Hansel, T.T., and C. Walker. 1993, The Handbook of Immunopharmacology: Immunopharmacology of Eosinophils. Academic Press Inc., San Diego, CA. 218 pp.
46. Kohl, J., B. Lubbers, A. Klos, W. Bautsch, and M. Casaretto. 1993. Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides. Eur. J. Immunol. 23: 646-652.
47. Bautsch, W., T. Kretzschmar, T. Stuhmer, A. Kola, M. Emde, J. Kohl, A. Klos, and D. Bitter-Suermann. 1992. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity. Biochem. J. 288: 261-266.
48. Wagner, J.L., and T.E. Hugh. 1984. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal. Biochem. 136: 75-88.
49. Moy, J.N., G.J. Gleich, andL.L. Thomas. 1990. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J. Immunol. 145: 2626-2632.
50. Moy, J.N., L.L. Thomas, andL.C. Whisler. 1993. Eosinophil major basic protein enhances the expression of neutrophil CR3 and pl50,95. J. Allergy Clin. Immunol. 92: 598-606.
51. Hansel, T.T., R.K. Braun, S. Rihs, I.J.M. De Vries, K. Blaser, F. Erard, A. Rot, I. Lindley, P. Dukor, and C. Walker. 1991. Interleukin 8 production by human peripheral blood eosinophils. Eighth Int. Cong. Immunol. 162. (Abstr.)
52. Braun, R.K., M. Franchini, F. Erard, S. Rihs, I.J.M. De Vries, K. Blaser, T.T. Hansel, and C. Walker. 1993. Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. Eur. J. Immunol. 23: 956-960.
53. Cromwell, O., A.J. Wardlaw, A. Champion, R. Moqbel, D. Osei, and A.B. Kay. 1990. IgG-dependent generation of plateletactivating factor by normal and low density human eosinophils. J. Immunol. 145: 3862-3868.
54. Koenderman, L., and P.L.B. Bruijnzeel. 1989. Increased sensitivity of the chemoattractant-induced chemiluminescence in eosinophils isolated from atopic individuals. Immunology. 67: 534-536.
55. Tomioka, K., D.W. MacGlashan, Jr., L.M. Lichtenstein, B.S. Bochner, and R.P. Schleimer. 1993. GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. J. Immunol. 151: 4989-4997.
56. Kirsch, C.M., E. Sigal, T.D. Djokic, P.D. Graf, andJ.A. Nadel. 1988. An in vivo chemotaxis assay in dog trachea: evidence for chemotactic activity of 8,15-diHETE. J. Appl. Physiol. 64: 1792-1795.
57. Shak, S., H.D. Perez, and I.M. Goldstein. 1983. A novel dioxygenation product of arachidonic acid possesses potent chemotactic activity for human polymorphonuclear leukocytes. J. Biol. Chem. 258: 14948-14953.
58. Erdos, E.G., and E.M. Sloane. 1962. An enzyme in human blood plasma that inactivates bradykinins and kallidins. Biochem. Pharmacol. 11: 585-592.
59. Huey, R., C.M. Bloor, M.S. Kawahara, and T.E. Hugli. 1983. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am. J. Pathol. 112: 48-60.
60. Bokisch, V.A., and H.J. Muller-Eberhard. 1970. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49: 2427-2436.
61. Gallin, J.I. 1994. Quantitative and qualitative disorders of phagocytes. In Harrison’s Principles of Internal Medicine. K.J. Isselbacher, E. Braunwald, J.D. Wilson, J.R Martin, A.S. Fauci, and D.L. Kasper, editors. McGraw-Hill Inc., New York. 329-337.
62. Matteson, E.L., M.D. Cohen, and D.L. Conn. 1994. Rheumatoid arthritis: clinical features-systemic involvement. In Rheumatology. J.H. Klippel and P.A. Dieppe, editors. Mosby, London. 5.1-5.8.
63. Shelley, W.B., and E.D. Shelley. 1992. Bullous diseases. In Advanced Dermatologic Diagnosis. W.B. Saunders Co., Philadelphia, PA. 378-421.